We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

5 hedge funds and large institutions have $5.16M invested in Tonix Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding

Funds holding: 3 → 5 (+2)

46% more capital invested

Capital invested by funds: $3.53M → $5.16M (+$1.63M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$820K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$820K
3
Squarepoint
Squarepoint
New York
+$410K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$79K
2
Citadel Advisors
Citadel Advisors
Florida
-$67K
3
OPS
Orion Portfolio Solutions
Nebraska
-$67K
4
JP Morgan Chase
JP Morgan Chase
New York
-$33K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.23M +$820K +2 +200%
BlackRock
2
BlackRock
New York
$993K – – –
GCP
3
GSA Capital Partners
United Kingdom
$770K +$820K +2 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$624K – – –
Squarepoint
5
Squarepoint
New York
$459K +$410K +1 New
Renaissance Technologies
6
Renaissance Technologies
New York
$183K – – –
BCM
7
Bridgeway Capital Management
Texas
$179K – – –
Northern Trust
8
Northern Trust
Illinois
$178K – – –
Wells Fargo
9
Wells Fargo
California
$126K – – –
Capstone Investment Advisors
10
Capstone Investment Advisors
New York
$120K – – –
Charles Schwab
11
Charles Schwab
California
$62K – – –
N
12
Natixis
France
$36K – – –
MA
13
MONECO Advisors
Connecticut
$35K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$32K – – –
Victory Capital Management
15
Victory Capital Management
Texas
$22K – – –
Principal Financial Group
16
Principal Financial Group
Iowa
$18K – – –
RFA
17
Reilly Financial Advisors
California
$17K – – –
EH
18
Equitable Holdings
New York
$14K – – –
LFG
19
Larson Financial Group
Missouri
$14K – – –
SGI
20
Summit Global Investments
Utah
$14K – – –
TI
21
tru Independence
Oregon
$10.1K – – –
SFS
22
Sowell Financial Services
Arkansas
$10K – – –
AWM
23
Alterna Wealth Management
Texas
$7K – – –
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.38K – – –
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$2K – – –
1
2

TNXP Hedge Fund Activity: Q4 2020 in Review

5 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2020, worth a combined $5.16M — up 46% from $3.53M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new TNXP positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $820K. The largest seller was Virtu Financial, cutting an estimated $79K.

  • 5 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q4 2020, up from 3 in Q3 2020.
  • Funds reported $5.16M of Tonix Pharmaceuticals stock for Q4 2020, up 46% quarter-over-quarter.
  • 2 funds opened new Tonix Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +2 holders.
  • The largest Tonix Pharmaceuticals buyer in Q4 2020 was GSA Capital Partners, an estimated $820K added.
  • The largest Tonix Pharmaceuticals seller in Q4 2020 was Virtu Financial, an estimated $79K sold.

Based on aggregated 13F filings for Q4 2020.